Viatris Wins First US Symbicort Generic – Will It Launch At Risk?
Federal Circuit Recently Told AstraZeneca It Would Not Review Viatris Win
Executive Summary
In the wake of a favorable US Court of Appeals for the Federal Circuit decision, Viatris has won FDA approval for the first generic Symbicort product. The ANDA sponsor’s management had recently declared itself “ready to launch if the opportunity presents itself in 2022.”
You may also be interested in...
Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.
Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.
Viatris Is ‘Not Walking Away’ From Generics
After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.